BLUE - bluebird bio, Inc.

4.97
0   0%

Share volume: 1,245,197
Last Updated: 05-30-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$4.97
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 0%
Dept financing 33%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
20.92%
2 Year
242.76%
Key data
Stock price
$4.97
P/E Ratio 
0.00
DAY RANGE
$4.67 - $5.03
EPS 
-$6.67
52 WEEK RANGE
$3.20 - $5.42
52 WEEK CHANGE
$24.25
MARKET CAP 
47.776 M
YIELD 
N/A
SHARES OUTSTANDING 
9.792 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
12-13-2024
NEXT EARNINGS DATE
05-08-2025
BETA 
0.83
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Andrew Obenshain
Region: US
Website: bluebirdbio.com
Employees: 520
IPO year: 2013
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

bluebird bio, Inc., researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc.

Recent news